Your browser doesn't support javascript.
loading
Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
Buyeverov, A O; Bogomolov, P O; Mayev, I V; Matsievich, M V; Uvarova, O V.
Afiliação
  • Buyeverov AO; M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia.
  • Bogomolov PO; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
  • Mayev IV; M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia.
  • Matsievich MV; A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation, Moscow, Russia.
  • Uvarova OV; Clinical Hospital of Centrosoyuz, Moscow, Russia.
Ter Arkh ; 91(2): 52-58, 2019 Mar 18.
Article em En | MEDLINE | ID: mdl-31094172
ABSTRACT

AIM:

Study of the social consequences of cognitive disorders in minimal hepatic encephalopathy (MHE) in patients with chronic genotype 1 hepatitis C and the possibilities of their pharmacological correction with L-ornithine-L-aspartate (LOLA, Hepa-Merz). MATERIALS AND

METHODS:

The study group included 60 male patients diagnosed with chronic hepatitis C, genotype 1 with fibrosis stage F1 according to the METAVIR scale, and presented with MHE. The average age of the patients was 34.2±5.3 years. The control group included 20 healthy men aged 34.1±5.8 years without liver disease. Intermittent treatment with LOLA was given to the study group at 15 g once daily in the morning for 2 months with 2-month off-treatment intervals, with the total treatment duration of 12 months. In the course of treatment, MHE dynamics was assessed using the critical flicker fusion frequency (CFF) test and the number connecting test (NCT), as well as by serum concentrations of ammonium ion. The LOLA efficacy endpoint was the change in the frequency of violations of traffic rules (traffic code).

RESULTS:

A significant decrease in the concentration of ammonium ion was observed after 5 months of treatment (135.53 and 82.9 µmol/L, p=0.002) and maintained throughout the study. The results of the CFF test significantly improved by the end of the 1st month of LOLA treatment (p=0.008), remaining at the achieved level for 9 months. The NCT parameters reached their minimum values after 5 months (p<0.001) and remained at this level throughout the study. During the study period, the frequency of traffic code violations by participants decreased from 60 to 40% (р=0.03).

CONCLUSION:

Fractional treatment with LOLA leads to a decrease in the blood concentration of ammonium ion and, consequently, to an improvement in psychometric test results and a decrease in the frequency of traffic code violations. The result achieved can have an impact on the accident rate reduction.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encefalopatia Hepática / Hepatite C Crônica / Hiperamonemia / Dipeptídeos Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans / Male Idioma: En Revista: Ter Arkh Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Federação Russa

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encefalopatia Hepática / Hepatite C Crônica / Hiperamonemia / Dipeptídeos Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Adult / Humans / Male Idioma: En Revista: Ter Arkh Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Federação Russa